Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients.
Gámez-Pozo A, Antón-Aparicio LM, Bayona C, Borrega P, Gallegos Sancho MI, García-Domínguez R, de Portugal T, Ramos-Vázquez M, Pérez-Carrión R, Bolós MV, Madero R, Sánchez-Navarro I, Fresno Vara JA, Espinosa Arranz E. Gámez-Pozo A, et al. Among authors: anton aparicio lm. Neoplasia. 2012 Dec;14(12):1144-52. doi: 10.1593/neo.12734. Neoplasia. 2012. PMID: 23308047 Free PMC article.
Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.
Castellano D, Maroto JP, Espinosa E, Grande E, Bolós MV, Llinares J, Esteban E, González Del Alba A, Climent MA, Arranz JA, Méndez MJ, Fernández Parra E, Antón-Aparicio L, Bayona C, Gallegos I, Gallardo E, Samaniego L, García Donas J. Castellano D, et al. Expert Opin Drug Saf. 2018 Jun;17(6):573-579. doi: 10.1080/14740338.2017.1330410. Epub 2017 Aug 28. Expert Opin Drug Saf. 2018. PMID: 28535693 Free article.
Molecular basis of hypertension side effects induced by sunitinib.
Aparicio-Gallego G, Afonso-Afonso FJ, León-Mateos L, Fírvida-Pérez JL, Vázquez-Estévez S, Lázaro-Quintela M, Ramos-Vázquez M, Fernández-Calvo O, Campos-Balea B, Antón-Aparicio LM. Aparicio-Gallego G, et al. Anticancer Drugs. 2011 Jan;22(1):1-8. doi: 10.1097/CAD.0b013e3283403806. Anticancer Drugs. 2011. PMID: 20938340 Review.
[Thrombotic thrombocytopenic purpura as presentation of a neoplasia].
Gallegos Sancho MI, Reboredo López M, García Campelo R, Quindós Varela M, Antón Aparicio LM. Gallegos Sancho MI, et al. An Med Interna. 2005 Aug;22(8):398. doi: 10.4321/s0212-71992005000800013. An Med Interna. 2005. PMID: 16358430 Spanish. No abstract available.
New insights into molecular mechanisms of sunitinib-associated side effects.
Aparicio-Gallego G, Blanco M, Figueroa A, García-Campelo R, Valladares-Ayerbes M, Grande-Pulido E, Antón-Aparicio L. Aparicio-Gallego G, et al. Mol Cancer Ther. 2011 Dec;10(12):2215-23. doi: 10.1158/1535-7163.MCT-10-1124. Mol Cancer Ther. 2011. PMID: 22161785 Review.
Circulating MicroRNAs in blood of patients with prostate cancer.
Medina-Villaamil V, Martínez-Breijo S, Portela-Pereira P, Quindós-Varela M, Santamarina-Caínzos I, Antón-Aparicio LM, Gómez-Veiga F. Medina-Villaamil V, et al. Among authors: anton aparicio lm. Actas Urol Esp. 2014 Dec;38(10):633-9. doi: 10.1016/j.acuro.2014.02.008. Epub 2014 Mar 21. Actas Urol Esp. 2014. PMID: 24661838 English, Spanish.
Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.
Feliu J, Vicent JM, García-Girón C, Constela M, Fonseca E, Aparicio J, Lomas M, Antón-Aparicio L, Dorta FJ, Gonzalez-Baron M; Oncopaz Cooperative Group and Associated Hospitals. Feliu J, et al. Br J Cancer. 2004 Nov 15;91(10):1758-62. doi: 10.1038/sj.bjc.6602217. Br J Cancer. 2004. PMID: 15505621 Free PMC article. Clinical Trial.
56 results